WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded. FT reporter Anna Mutoh examines whether WeightWatchers’ latest strategy can produce the turnaround investors are hoping for.
Clip from Lionsgate Television
- - - - - - - - - - - - - - - - - - - - - - - - - -
For further reading:
WeightWatchers faces an era when weight loss comes in a syringe
Behold the Ozempic effect on business
The race to develop the next generation of weight-loss drugs
- - - - - - - - - - - - - - - - - - - - - - - - - -
On X, follow Anna Mutoh (@anna_mutoh) and Michela Tindera (@mtindera07), or follow Michela on LinkedIn for updates about the show and more.
Read a transcript of this episode on FT.com
Hosted on Acast. See acast.com/privacy for more information.
What next for Detroit's carmakers
Pharma raises its bet on biotech
China's Didi adds finance to the mix
Huawei and the fight for 5G
IBM's next move
The oil sell-off explained
Investors fear 'peak iPhone'
How €200bn of ‘dirty money’ flowed through a Danish bank
The future of dealmaking with Saudi Arabia
The rise and fall of General Electric
Tune in Wednesday
Private equity's debt mountain (encore episode)
Tilray and the cannabis trade
On the front lines of the crisis
Purdue Pharma's 'one-two' punch
Following the cannabis money trail (encore episode)
Khosrowshahi's year at the wheel
Digging into student debt
Taking Tesla private
Tesla’s rough ride
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
FT News Briefing
Money Clinic with Claer Barrett
FT World Weekly
FT News in Focus
FT Banking Weekly